Table 1. Characteristics of study group consisting of women with breast cancer.
Women with BC history, menopausal and their tumor grade and receptor status (estrogen, HER2, progesterone) classification expressed as numerical and % values (n = 270).
| Variables | Summary measures(N = 270) |
|---|---|
| N (%) | |
| DRC (%)* | 3.05 ± 2.8 |
| Median DRC (P25, P75) | 2.1 (1.24%, 4.07%) |
| DRC (tertiles) | |
| < 1.6% | 90 (33.3) |
| 1.6–3.2% | 90 (33.3) |
| > 3.2% | 90 (33.3) |
| Age | |
| < 45 | 50 (18.5) |
| 46–55 | 79 (29.3) |
| 56–65 | 75 (27.8) |
| > 65 | 66 (24.4) |
| Median Age (SD) | 56.4 ± 12.2 |
| History of breast cancer | |
| Yes | 67 (24.8) |
| No | 203 (75.2) |
| Menopausal status | |
| Yes | 174 (64.4) |
| No | 96 (35.6) |
| Multivitamin consumption in the last 5 years | |
| Yes | 66 (25.2) |
| No | 204 (74.8) |
| Calcium consumption in the last 5 years | |
| Yes | 46 (17.6) |
| No | 224 (82.4) |
| Tumor grade | |
| I | 31 (12.6) |
| II | 127 (51.6) |
| III | 88 (35.8) |
| Missing | 24 |
| Receptor status | |
| Estrogen Receptor | |
| Negative | 73 (27.0) |
| Positive | 197 (73.0) |
| HER2 Receptor | |
| Negative | 206 (76.3) |
| Positive | 64 (23.7) |
| Progesterone Receptor | |
| Negative | 100 (37.0) |
| Positive | 170 (63.0) |
* Value of % DNA repair capacity (DRC) measured in lymphocytes expressed as mean (), ± 1 standard deviation (SD) and median values including percentile 25 (P25) and percentile 75 (P75).